Renhaim CEO, Tae-Jin Kang participated in the Cancer Science held at National Cancer Center on 27 May 2022.
With more than 500 concerned participants and experts from MFDS, mRNA based technology companies, and medical research, CEO Kang participated in the second panel discussing while sharing various challenges in developing mRNA cancer vaccines and stressing the importance of collaboration among industry, academia, and clinicians. In addition, CEO Kang explained about the future plan for developing mRNA based cancer vaccines through ecosystem.
Please refer to the article below to learn more about mRNA cancer vaccine of Renhaim.
